Effector mechanisms of nonsuppurative destructive cholangitis in graft-versus-host disease and allograft rejection

Seminars in Liver Disease

Volumn 25, Issue 3, 2005, Pages 281-297

  Adams, David H ^a   Afford, Simon C ^a  

^a Medical School   (United Kingdom)

Author keywords

Apoptosis; CD40; Fas; GVHD; Liver allograft rejection; Vanishing bile duct syndrome

Indexed keywords

CD40 ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; GRANZYME A; PERFORIN; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; AUTOCRINE EFFECT; CHOLANGITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; EFFECTOR CELL; GASTROINTESTINAL INFECTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LIGAND BINDING; LYMPHOCYTIC INFILTRATION; MOLECULAR MODEL; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW;

APOPTOSIS; BILE DUCTS; CELL ADHESION MOLECULES; FAS LIGAND PROTEIN; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS, BILIARY; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 24344449036     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916320     Document Type: Review

References (191)

1. Burt AD. Primary biliary cirrhosis and other ductopenic diseases. Clin Liver Dis 2002;6:363-380
2. Hubscher SG. Histological findings in liver allograft rejection-new insights into the pathogenesis of hepatocellular damage in liver allografts. Histopathology 1991;18: 377-383
3. Hubscher SG. Pathology of liver allograft rejection. Transpl Immunol 1994;2:118-123
4. Scheuer PJ. Ludwig Symposium on biliary disorders-part II. Pathologic features and evolution of primary biliary cirrhosis and primary sderosing cholangitis. Mayo Clin Proc 1998;73: 179-183
5. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000;95:1130-1138
6. Celli A, Que FG. Deregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998;18:177-185
7. Chen XM, Gores GJ, Paya CV, LaRusso NF. Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. Am J Physiol 1999;277: G599-G608
8. Patel T, Gores GJ. Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. Liver Transpl Surg 1998;4:42-50
9. Vierling JM. Animal models for primary sderosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:591-610
10. Vierling JM. Autoimmune cholangiopathy. Clin Liver Dis 1999;3:571-S84
11. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg 1999;5(4 suppl 1):S1-S20
12. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003;21:149-161
13. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev 2003;17:187-194
14. Jamieson NV, Joysey V, Friend PJ, et al. Graft-versus-host disease in solid organ transplantation. Transpl Int 1991;4: 67-71
15. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastroenterology 1986;90:460-477
16. Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991;52:1014-1019
17. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation. Part II. Gastroenterology 1986;90:770-784
18. Diamond DJ, Chang KL, Jenkins KA, Forman SJ. Immunohistochemical analysis of T cell phenotypes in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1995;59: 1436-1444
19. Tanaka M, Umihara J, Shimmoto K, et al. The pathogenesis of graft-versus-host reaction in the intrahepatic bile duct. An immunohistochemical study. Acta Pathol Jpn 1989;39:648-655
20. Hubscher SG, Adams DH, Buckels JA, McMaster P, Neuberger J, Elias E. Massive haemorrhagic necrosis of the liver after liver transplantation. J Clin Pathol 1989;42:360-370
21. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998;29:143-150
22. Vierling JM, Fennell RH Jr. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology 1985;5: 1076-1082
23. Dousset B, Hubscher SG, Padbury RT, et al. Acute liver allograft rejection-is treatment always necessary? Transplantation 1993;55:529-534
24. Goddard S, Adams DH. New approaches to immunosuppression in liver transplantation. J Gastroenterol Hepatol 2002;17:116-126
25. Neil DA, Adams DH, Gunson B, Hubscher SG. Is chronic rejection of liver transplants different from graft arteriosclerosis of kidney and heart transplants? Transplant Proc 1997;29:2539-2540
26. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 1991;13:882-891
27. Snover DC, Freese DK, Bloomer JR, Sharp HL, Ascher NL. An analysis of histological prognostic features of liver allograft rejection based on 270 serial biopsies. Transplant Proc 1987;19(1 pt 3):2457-2458
28. Lunz JG III, Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001;158:1379-1390
29. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile- duct loss in human liver allograft-rejection. Transplantation 1993;56:69-75
30. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999;30:811-815
31. Fausto N. Liver regeneration. J Hepatol 2000;32(suppl 1): 19-31
32. Palmer JM, Kirby JA, Jones DE. The immunology of primary biliary cirrhosis: the end of the beginning? Clin Exp Immunol 2002;129:191-197
33. Kita H, Mackay IR, Van de Water J, Gershwin ME. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001;120:1485-1501
34. Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-225
35. Adams DH, Afford SC. The role of cholangiocytes in the development of chronic inflammatory liver disease. Front Biosci 2002;7:e276-e285
36. Vierling JM. Immunological mechanisms of hepatic allograft rejection. Semin Liver Dis 1992;12:16-27
37. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004;75:5-17
38. Mahida YR, Cunliffe RN. Defensins and mucosal protection. Novartis Found Symp 2004;263:71-77
39. Nozaki I, Lunz JG III, Specht S, et al. Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol 2004;165:1907-1920
40. Reynoso-Paz S, Coppel RL, Mackay IR, Bass NM, Ansari AA, Gershwin ME. The immunobiology of bile and biliary epithelium. Hepatology 1999;30:351-357
41. Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman JP, Lamm ME. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci USA 1991;88:8796-8800
42. Lamm ME. Current concepts in mucosal immunity. IV. How epithelial transport of IgA antibodies relates to host defense. Am J Physiol 1998;274(4 pt 1):G614-G617
43. Coulomb-L'Hermin A, Amara A, Schiff C, et al. Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cells. Proc Natl Acad Sci USA 1999;96:8585-8590
44. Terada R, Yamamoto K, Hakoda T, et al. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest 2003;83:665-672
45. Morland CM, Fear J, McNab G, Joplin R, Adams DH. Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians 1997;109:372-382
46. Loffreda S, Rai R, Yang SQ, Lin HZ, Diehl AM. Bile ducts and portal and central veins are major producers of tumor necrosis factor alpha in regenerating rat liver. Gastroenterology 1997;112:2089-2098
47. Dienes HP, Lohse AW, Gerken G, et al. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 1997;431:119-124
48. Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA. Immunogenicity of biliary epithelium: study of the adhesive interaction with lymphocytes. Gastroenterology 1997;112: 968-977
49. Saxena R, Hytiroglou P, Thung SN, Theise ND. Destruction of canals of Hering in primary biliary cirrhosis. Hum Pathol 2002;33:983-988
50. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 1993;3:261-275
51. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252
52. Reis e Sousa C. Dendritic cells as sensors of infection. Immunity 2001;14:495-498
53. Muller WA, Randolph GJ. Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukoc Biol 1999;66:698-704
54. Kudo S, Matsuno K, Ezaki T, Ogawa M. A novel migration pathway for rat dendritic cells from the blood: hepatic sinusoids-lymph translocation. J Exp Med 1997;185:777-784
55. Matsuno K, Kudo S, Ezaki T. The liver sinusoids as a specialized site for blood-lymph translocation of rat dendritic cells. Adv Exp Med Biol 1997;417:77-81
56. Uwatoku R, Suematsu M, Ezaki T, et al. Kupffer cell-mediated recruitment of rat dendritic cells to the liver: roles of N-acetylgalactosamine-specific sugar receptors. Gastroenterology 2001;121:1460-1472
57. Mempel TR, Henrickson SE, von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-159
58. Cremer I, Dieu-Nosjean MC, Marechal S, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002;100:3646-3655
59. Goddard S, Youster J, Morgan E, Adams DH. Interleukin-10 secretion differentiates dendritic cells from human liver and skin. Am J Pathol 2004;164:511-519
60. Csencsits K, Wood SC, Lu G, et al. Graft rejection mediated by CD4(+) T cells via indirect recognition of alloantigen is associated with a dominant Th2 response. Eur J Immunol 2005;35:843-851
61. Stanford RE, Ahmed S, Hodson M, Banner NR, Rose ML. A role for indirect allorecognition in lung transplant recipients with obliterative bronchiolitis. Am J Transplant 2003;3:736-742
62. Thomson AW, Lu L. Dendritic cells as regulators of immune reactivity: implications for transplantation. Transplantation 1999;68:1-8
63. Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol 1989;143: 476-483
64. Vierling JM, Howell CD. Disappearing bile ducts: immunologic mechanisms. Hosp Pract (Off Ed) 1990;25:141-150
65. McCaughan GW, Davies JW, Waugh JA. A quantitative analysis of T-lymphocyte populations in human liver allografts undergoing rejection. Hepatology 1990;12:1305-1313
66. McCaughan GW, Bishop GA. Atherosclerosis of the liver allograft. J Hepatol 1997;27:592-598
67. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003;111:659-669
68. Masubuchi Y, Kawaguchi T, Ohtsuki M, et al. FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats. Transplant Proc 1996;28:1064-1065
69. Azhipa O, Kimizuka K, Nakao A, et al. Comparative analysis of the fate of donor dendritic cells and B cells and their influence on alloreactive T cell responses under tacrolimus immunosuppression. Clin Immunol 2005;114: 199-209
70. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003;196:125-146
71. McCaughan GW, Gorrell MD, Bishop GA, et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev 2000;174:172-191
72. Lalor PF, Shields P, Grant A, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol 2002; 80:52-64
73. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000;12:336-341
74. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-1034
75. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928
76. Gretz JE, Kaldjian EP, Anderson AO, Shaw S. Commentary-sophisticated strategies for information encounter in the lymph-node - the reticular network as a conduit of soluble information and a highway for cell traffic. J Immunol 1996;157:495-499
77. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 1993;361:79-82
78. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-3860
79. Klugewitz K, Adams DH, Emoto M, Eulenburg K, Hamann A. The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol 2004;25:590-594
80. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003;3:51-62
81. Adams DH, Hubscher S, Fear J, Johnston J, Shaw S, Afford S. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation 1996;61:817-825
82. Goddard S, Williams A, Morland C, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001;72:1957-1967
83. Steinhoff G, Behrend M, Wonigeit K. Expression of adhesion molecules on lymphocytes/monocytes and hepatocytes in human liver grafts. Hum Immunol 1990;28:123-127
84. Steinhoff G, Behrend M, Schrader B, Pichlmayr R. Intercellular immune adhesion molecules in human liver transplants: overview on expression patterns of leukocyte receptor and ligand molecules. Hepatology 1993;18:440-453
85. Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999;163:3202-3210
86. Hamann A, Klugewitz K, Austrup F, Jablonski-Westrich D. Activation induces rapid and profound alterations in the trafficking of T cells. Eur J Immunol 2000;30:3207-3218
87. Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol 2002;169:2407-2413
88. Itoh Y, Morita A, Nishioji K, et al. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat 2001;8:341-348
89. Narumi S, Tominaga Y, Tamaru M, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997;158:5536-5544
90. Yoong KF, Afford SC, Jones R, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999;30:100-111
91. Tamaru M, Nishioji K, Kobayashi Y, et al. Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine 2000;12:299-308
92. Kim CH, Kunkel EJ, Boisvert J, et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001; 107:595-601
93. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005;174:1055-1062
94. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999;163:6236-6243
95. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005;105:4191-4199
96. 96a. Ichiba T, Teshima T, Kuick R, et al. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood 2003;102:763-771
97. 96b. Curbishley SM, Eksteen B, Lalor PF, Adam DH. CXCR3 activation promotes lymphocyte transendothelial migration across hepatic endothelium under conditions of flow. Am J Pathol 2005; (in press)
98. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003;31:897-902
99. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104:49-57
100. New JY, Li B, Koh WP, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002;29:979-986
101. Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a dass I but not class II major histocompatibility complex barrier. Blood 1999;93: 43-50
102. Adams DH, Hubscher SG, Fisher NC, Williams A, Robinson M. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996;24:533-538
103. Wong J, Johnston B, Lee SS, et al. A minimal role for selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J Clin Invest 1997;99:2782-2790
104. Later PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983-992
105. Adams DH, Hubscher SG, Shaw J, Rothlein R, Neuberger JM. Intercellular adhesion molecule 1 on liver allografts during rejection. Lancet 1989;2:1122-1125
106. Harning R, Koo GC, Szalay J. Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Vis Sci 1989;30:1909-1915
107. Wong J, Kubes P, Zhang Y, et al. Role of ICAM-1 in chronic hepatic allograft rejection in the rat. Am J Physiol Gastrointest Liver Physiol 2002;283:G196-G203
108. Gassel HJ, Otto C, Gassel AM, et al. Tolerance of rat liver allografts induced by short-term selective immunosuppression combining monoclonal antibodies directed against CD25 and CD54 with subtherapeutic cyclosporine. Transplantation 2000;69:1058-1067
109. Panoskaltsis-Mortari A, Hermanson JR, Haddad IY, Wangensteen OD, Blazar BR. Intercellular adhesion molecule-I (ICAM-I, CD54) deficiency segregates the unique pathophysiological requirements for generating idiopathic pneumonia syndrome (IPS) versus graft-versus-host disease following allogeneic murine bone marrow transplantation. Biol Blood Marrow Transplant 2001;7: 368-377
110. Martelius T, Salaspuro V, Salmi M, et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am J Pathol 2004;165:1993-2001
111. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. Gut 1993;34:1245-1249
112. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221-227
113. Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol 1995; 175:319-325
114. Liang Y, Sasaki K. Expression of adhesion molecules relevant to leukocyte migration on the microvilli of liver peritoneal mesothelial cells. Anat Rec 2000;258:39-46
115. Bloom S, Fleming K, Chapman R, Neuberger J, Hubscher S. Inappropriate expression of blood-group antigens in hepatic allografts. Hepatology 1994;19:876-881
116. Isse K, Harada K, Zen Y, et al. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005;41:506-516
117. Efsen E, Grappone C, Defranco RM, et al. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002;37:39-47
118. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298-304
119. Wilbanks A, Zondlo SC, Murphy K, et al. Expression doning of the str133/bonzo/tymstr ligand reveals elements of cc, cxc, and cx3c chemokines. J Immunol 2001;166:5145-5154
120. Sharron M, Pohlmann S, Price K, et al. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 2000;96:41-49
121. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001;166:6477-6482
122. Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, Greenberg HB. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 2003;38:67-75
123. Sato T, Thorlacius H, Johnston B, et al. Role for CXCR6 in recruitment of activated CD8+ lymphocytes to inflamed liver. J Immunol 2005;174:277-283
124. Leon MP, Bassendine MF, Wilson JL, Ali S, Thick M, Kirby JA. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology 1996;24:561-567
125. Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA. Immunogenicity of biliary epithelium: study of the adhesive interaction with lymphocytes. Gastroenterology 1997; 112(3):968-977
126. Dollinger MM, Howie SE, Plevris JN, Graham AM, Hayes PC, Harrison DJ. Intrahepatic proliferation of 'naïve' and 'memory' T cells during liver allograft rejection: primary immune response within the allograft. FASEB J 1998;12: 939-947
127. Yang ZF, Ho DW, Chu AC, Wang YQ, Fan ST. Linking inflammation to acute rejection in small-for-size liver allografts: the potential role of early macrophage activation. Am J Transplant 2004;4:196-209
128. Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol 1985;3:31-58
129. Atkinson EA, Bleackley RC. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 1995;15:359-384
130. Simon MM, Waring P, Lobigs M, et al. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J Immunol 2000;165:3663-3672
131. Smyth MJ, Kelly JM, Sutton VR, et al. Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001;70:18-29
132. Lieberman J, Fan Z. Nuclear war: the granzyme A-bomb. Curr Opin Immunol 2003;15:553-559
133. Bossi G, Griffiths GM. CTL secretory lysosomes: biogenesis and secretion of a harmful organelle. Semin Immunol 2005; 17:87-94
134. Bossi G, Trambas C, Booth S, Clark R, Stinchcombe J, Griffiths GM. The secretory synapse: the secrets of a serial killer. Immunol Rev 2002;189:152-160
135. Ryo R, Saigo K, Hashimoto M, et al. Treatment of posttransfusion graft-versus-host disease with nafamostat mesylate, a serine protease inhibitor. Vox Sang 1999;76:241-246
136. Graubert TA, Dipersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997;100:904-911
137. Pham CT, Ley TJ. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin Immunol 1997;9: 127-133
138. Kuijf ML, Kwekkeboom J, Kuijpers MA, et al. Granzyme expression in fine-needle aspirates from liver allografts is increased during acute rejection. Liver Transpl 2002;8:952-956
139. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997;26:1399-1405
140. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001;120:190-199
141. Nathan C, Muller WA. Putting the brakes on innate immunity: a regulatory role for CD200? Nat Immunol 2001; 2:17-19
142. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999;189:441-446
143. Afford SC, Ahmed-Choudhury J, Randhawa S, et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells. FASEB J 2001;15:2345-2354
144. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65
145. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809
146. [published erratum: Nature 1993;365: 568]
147. Lacronique V, Mignon A, Fabre M, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996;2:80-86
148. Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230
149. Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 1998;275(3 pt 1):G387-G392
150. Ahmed-Choudhury J, Russell CL, Randhawa S, et al. Differential induction of nuclear factor-kappaB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Biol Cell 2003;14:1334-1345
151. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-1456
152. Beyaert R, Van LG, Heyninck K, Vandenabeele P. Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas. Int Rev Cytol 2002;214:225-272
153. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209
154. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004;73:87-106
155. Bossi G, Stinchcombe JC, Page LJ, Griffiths GM. Sorting out the multiple roles of Fas ligand. Eur J Cell Biol 2000; 79:539-543
156. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 1999;5:90-96
157. Kojima Y, Kawasaki-Koyanagi A, Sueyoshi N, Kanai A, Yagita H, Okumura K. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity. Biochem Biophys Res Commun 2002;296:328-336
158. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36
159. Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503-5515
160. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane- anchored TNF. EMBO J 1999;18: 3034-3043
161. Van Kooten C, Bancherau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997;9: 330-337
162. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998;19:502-506
163. Schmitz ML, Mattioli I, Buss H, Kracht M. NF-kappaB: a multifaceted transcription factor regulated at several levels. ChemBioChem 2004;5:1348-1358
164. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997;6:379-387
165. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556
166. Levy DE, Lee CK. What does Stat3 do? J Clin Invest 2002;109:1143-1148
167. Kusters S, Tiegs G, Alexopoulou L, et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997;27:2870-2875
168. Stephens J, Cosyns M, Jones M, Hayward A. Liver and bile duct pathology following cryptosporidium parvum infection of immunodeficient mice. Hepatology 1999;30:27-35
169. Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency and hyper-IgM. J Immunol 1997; 158:977-983
170. Guillonneau C, Louvet C, Renaudin K, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 2004;172:1619-1629
171. Mehling A, Loser K, Varga G, et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med 2001; 194:615-628
172. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-4925
173. Yellin MJ, Winikoff S, Fortune SM, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 1995;58:209-216
174. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156:3952-3960
175. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135
176. Streetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119: 446-460
177. Plumpe J, Malek NP, Bock CT, Rakemann T, Manns MP, Trautwein C. NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol 2000;278:G173-G183
178. Liedtke C, Trautwein C. A protective role of Stat3 in Fas mediated apoptosis of the liver. J Hepatol 2004;40:874-875
179. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821-831
180. Mori E, Thomas M, Motoki K, et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004;11:203-207
181. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-348
182. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-8633
183. Mundt B, Kuhnel F, Zender L, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003;17:94-96
184. Zender L, Hutker S, Mundt B, et al. NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Hepatology 2005;41:280-288
185. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38610-38618
186. Colell A, Coll O, Garcia-Ruiz C, et al. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology 2001;34:964-971
187. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr Mol Med 2003;3:483-490
188. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-176
189. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H. Cutting edge:
190. Harlan DM, Kirk AD. The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA 1999; 282:1076-1082
191. Swain MG, et al. Hepatology 2005; (in press)